Capricor Therapeutics (CAPR) Total Current Liabilities (2010 - 2026)

Capricor Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $33.6 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 50.59% year-over-year to $33.6 million; the TTM figure through Mar 2026 stood at $33.6 million (up 50.59% YoY), while the FY2025 annual figure was $35.8 million, up 70.44% from the prior year.
• Total Current Liabilities was $33.6 million for Q1 2026 at Capricor Therapeutics, down from $35.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $37.1 million in Q1 2023 to a low of $14.3 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $26.8 million across 5 years, with a median of $26.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities surged 676.18% in 2022, then plunged 37.81% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $23.6 million in 2022, then jumped by 32.57% to $31.3 million in 2023, then sank by 32.76% to $21.0 million in 2024, then surged by 70.44% to $35.8 million in 2025, then declined by 6.14% to $33.6 million in 2026.
• The last three Total Current Liabilities figures came in at $33.6 million (Q1 2026), $35.8 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.